Exonics Therapeutics closed on a $40 million Series A financing. It was led by The Column Group.
Tokyo-based Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for a total of $390 million. Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013. Under that deal, the two companies collaborated on discovering and developing drugs that target mitochondrial function. The most advanced program from the collaboration is MA-0211, which is presently in Phase I clinical trials for Duchenne muscular dystrophy (DMD). Astellas is an equity investor in Mitobridge already, and is paying $165.5 million in cash in addition to the $60 million in equity it already owns. There is also an additional $225 million in potential milestone payments. John Carroll, with Endpoints News, writes, “For years now, Salk’s Ron Evans—a celebrated serial entrepreneur in scientific circles—has been concentrating on the potential of a new pathway for turning your average couch potato rodent into Mighty Mouse—without exercise…. A couple of ...
Codiak intends to use the proceeds of the Series C financing to advance its initial product candidates into clinical trials, and to continue to develop the company's transformational exosome therapeutic platform.
French startup Doctolib is raising money for the second time in the past twelve months. The company is building a sort of Salesforce for the healthcare industry with a big emphasis on bookings. Doctolib just raised $42 million (€35 million) from Eurazeo and existing investor Bpifrance.
Medeor Therapeutics announced it had closed on an oversubscribed Series B financing worth $57 million. The round was led by RA Capital Management. New investors included Sofinnova Ventures and 6 Dimensions Capital. They were joined by existing investors Vivo Capital and WuXi Healthcare Ventures.
Amgen’s VC wing has invested in Fortuna Fix to help move autologous neural stem cells into the clinic. The $25 million series B sets regenerative medicine startup Fortuna up to move candidates against Parkinson’s disease and spinal cord injury to clinical trials next year.
Genetic testing startup Prenetics has raised $40 million in a Series B funding round led by Hong Kong-based venture capital fund Beyond Ventures and the Alibaba Hong Kong Entrepreneurs Fund.
Medical equipment maker MagicMed Technologies (Beijing) Co. has secured USD1.5 million (CNY10 million) in pre-series A financing. The funds will help the firm hasten the commercialization of its Magitor Cell, a single channel electrocardiographic monitoring device.
InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced a $ 55M Series D financing and investment round.
Cardiologs Technologies said this week it raised $6.4 million in a Series A round of financing to support accelerated commercialization of its Cardiologs ECG Analysis Platform in the US and Europe.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.